Carna Biosciences, Inc.
Notice of Clinical Trial Agreement Execution (monzosertib)
Carna Biosciences, Inc. has executed a Clinical Trial Agreement with The University of Texas MD Anderson Cancer Center for an investigator-initiated trial (IIT) using monzosertib (AS-0141). The trial targets relapsed or refractory AML and is a Phase 1b study evaluating the safety, tolerability, and efficacy of monzosertib as monotherapy and in a three-drug combination with AZA/VEN. The company will supply monzosertib and cover trial-related costs. There is no impact on consolidated earnings forecasts for the fiscal year ending December 2026.
Key Figures
- Supply of monzosertib and coverage of trial-related costs (specific amount unknown)
- Exchange information: JPY/USD 0.00634236062662523 (acquisition date 2026-10-02)
- Impact on consolidated earnings forecast is "Unknown" but stated as no impact (fiscal year ending December 2026)
AI要約
Business / Partnership Highlights
Carna Biosciences, Inc. has executed a Clinical Trial Agreement with The University of Texas MD Anderson Cancer Center for an investigator-initiated trial (IIT) targeting monzosertib (AS-0141). This Phase 1b trial will enroll patients with relapsed or refractory AML to evaluate the safety, tolerability, and efficacy of monzosertib as a single agent and in a three-drug combination with azacitidine/venetoclax (AZA/VEN). The company will supply the necessary monzosertib and bear trial-related costs. The principal investigator is Dr. Abhishek Maiti, and the trial will proceed under the policies of MD Anderson Cancer Center.
Impact for Shareholders & Outlook
The trial aims to develop new therapeutic options and accumulate important data to improve treatment outcomes in the AML field. There is no impact on consolidated earnings forecasts for the fiscal year ending December 2026. Registration updates on ClinicalTrials.gov will be made in accordance with MD Anderson Cancer Center policy, and the company will not normally provide separate notifications.
Carna Biosciences, Inc.
Company overview · Stock price · Financial data · All IR
